ClinicalTrials.gg
RecruitingNCT06631339LightSPANUpdated Sep 23, 2025

Optimizing Light Exposure for Myopia Prevention and Control (LightSPAN)

An interventional study of Light Intervention and Digital Intervention in Myopia, Light; Therapy, Complications and Myopia Progression, sponsored by National University of Singapore. Recruiting at 5 sites in Singapore. Open to participants aged 7 Years to 10 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-23.

Sponsored by National University of Singapore · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.
Phase
Not applicable
Study type
Interventional
Enrollment
396
Allocation
Randomized
Ages
7 Years to 10 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate whether the optimization of daily exposure to light in primary school children can lead to better myopia prevention and control. The trial also aims to better understand the impact of light exposure on sleep and cognitive performance in children.

This trial has 3 arms namely, (1) a technical intervention arm, (2) a digital intervention arm, and (3) a control arm.

  1. technical intervention - which involves changing of classroom lighting in primary schools to ceiling lights that mimic the spectral composition of sunlight and fluctuates in intensity. Parents of children within that arm will have a sham smart-phone application (s-LightUP)
  2. digital intervention - which involves standard classroom lighting and giving parents an interventional smart-phone application (i-LightUP) that will be coupled with their child's light and activity sensor (wrist worn device ). The interventional app will provide individually tailored recommendation based on their children's behaviour (data feedback that is collected from the light and activity monitoring watch). The interventional app would then send reminder prompts/notifications to encourage parents help their children achieve required amounts of myopia-preventive light quantum target set per day.
  3. Standard care or control group which involves standard classroom lighting and parents having a sham smart-phone application (s-LightUP)

Participants will:

  • be randomised to receive either no intervention (control group), technical intervention (light intervention that mimics sunlight) or digital intervention (parents having an app that syncs with child's light and activity sensor which will provide feedback to parents to encourage and recommends increment of outdoor activities and hours).
  • have their myopia progression monitored every 6 monthly and cognitive assessment done once every 3 months over a year.
  • wear the light and activity sensor watches throughout the 1-year study period as much as possible (minimum 1 week per month) except for wet water activities such as swimming, diving and showering for research data collection purpose.
Read the detailed description

The primary objective of the study is to evaluate whether the optimization of daily exposure to light in primary school children can lead to better myopia prevention and control. To do so, we will evaluate the effectiveness, safety and feasibility of:

  1. Arm 1: technical intervention which involves spectro-temporal refinement of classroom lighting in primary schools using full spectrum light emitting diodes (LEDs) (CCT: 4000K) in addition to intermittent fluctuations in light levels. Parents of children in that arm will have access to a sham version of the LightUP mobile application to facilitate communication with the study team and questionnaire collection during the study.
  2. Arm 2: digital intervention which involves optimization of daily light exposure using an individualised behaviour-changing smart-phone application (Interventional LightUP application) coupled with child-worn light and activity sensors to provide parents with an individually tailored recommendation to adapt their children's behaviour and provide them with the required amounts of myopia-preventive light quantum/day. + standard classroom lighting

    As compared to:

  3. Arm 3: Standard care or control group which involves standard classroom lighting and no access to the interventional version of the LightUP application. Parents of children in that arm will have access to a sham version of the LightUP mobile application to facilitate communication with the study team and questionnaire collection during the study.

Our study will also lead to the following scalable and implementable outcomes:

  1. evidence-based lighting designs and policy recommendations for classrooms;
  2. a user-friendly, smart digital eyecare companion that aligns perfectly with Singapore's Smart Nation Initiative.

A secondary objective of this study is to better understand the impact of light exposure on sleep and cognitive performance in children. This will be achieved through continuous wrist actigraphy monitoring and through cognitive assessments, performed in classrooms, using tablets (one tablet/child). The assessment consists of validated, child-adapted, higher cognitive tasks testing the following constructs: impulse control, spatial working memory, content working memory, cognitive flexibility, reaction time, and processing speed.

02

Conditions studied

  • Myopia
  • Light; Therapy, Complications
  • Myopia Progression
  • Short-Sighted
  • Myopia; Refractive Error

Keywords

  • Light Exposure
  • Digital Intervention
  • Myopia
  • Myopia Prevention
  • Cognition
  • Light Intervention
  • Behaviour changing phone application
  • Classroom
  • School-based
  • School
  • Singapore
  • Primary School
  • Light therapy
  • Myopia-control
03

In context

Myopia

1,159 studies on the registry are indexed under Myopia; 225 are open to participants now.

This study's planned enrollment of 396 is above the median of 78 across 923 interventional studies indexed under Myopia.

Browse Myopia studies →

Lead sponsor

National University of Singapore is the lead sponsor of 212 studies on the registry; 54 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
7 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must meet all the inclusion criteria below to participate in this study.

    1. Written form from parent / legal guardian and assent from child subject has been obtained
    2. Is between 7 to 10 years of age at start of study intervention which is 2 January 2025 or 1 January 2026
    3. Studying in either Primary 2 or 3 classes of the participating school(s) in academic year 2025 or 2026.
    4. Presenting visual acuity or best corrected visual acuity (BCVA) better or equal to LogMAR 0.2 (equivalent to Snellen 6/9 or better) in each eye
    5. Normal Intraocular pressure (not more than 21mmHg)
    6. No ocular conditions (e.g., optic nerve disease, glaucoma, retinal diseases) except for refractive error.
    7. No ocular conditions affecting the accuracy of the ophthalmic examinations
    8. In good general health with no significant systemic diseases that may affect eye health

Exclusion criteria

Exclusion Criteria:

  • All subjects meeting any of the exclusion criteria at baseline will be excluded from participation.

    1. Previous or ongoing myopia control treatment (including but not limited to orthokeratology, atropine, pirenzepine, myopia control spectacle and contact lenses, light therapy)
    2. Ongoing participation in other myopia prevention and control research trials
    3. Any systemic or neurologic diseases (e.g. cancer, epilepsy, Kawasaki disease) known to affect eye health or make the participant vulnerable to the ophthalmic examinations (e.g., light flash)
    4. Any other conditions precluding adherence to the protocol including unwillingness to refrain from myopia control treatment for the duration of the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
396 participants (estimated)

Study arms

  • Experimental
    Technical Intervention (n=132)

    Technical refinement of classroom lighting + Sham LightUP phone application (s-LightUP)

    Other: Light Intervention

  • Experimental
    Digital Intervention (n=132)

    Standard classroom lighting + Interventional LightUP phone application (i-LightUP)

    Behavioral: Digital Intervention

  • Placebo comparator
    Control Group (n=132)

    Standard care or control group which involves standard classroom lighting + Sham LightUP app (s-LightUP).

    Other: Control Group

Interventions

  • OtherLight Intervention

    LEDs mimicking the spectrum of sunlight (4000K) administered daily for 1 academic year, every school day, for the entire school day. The light levels generated by these LEDs will fluctuate throughout the day but will remain under 1000 lux.

  • BehavioralDigital Intervention

    Smart-phone application (LightUP) will be synced daily to a child-worn light and activity sensor and will allow parents to track their children's outdoor time and exposure to brighter light levels across the day. The application will also nudge parents to increase their child's exposure to light (e.g., increase time outdoors, or sitting next to a window indoors) after school hours for better myopia prevention and control. i-LightUP aims to gradually assist parents in helping their children reach the ultimate goal of spending at least 2 hours per day in brighter light conditions (e.g., above 1000 lux).

  • OtherControl Group

    Standard Classroom Lighting + Sham LightUP phone application

06

What researchers measure

Primary outcomes

  1. Cycloplegic auto-refraction

    Measured using autoref/kerato/pachy/tonometer

    Time frame: 1 year, once every 6 months (Baseline, Month 6, Month 12 Visit)

  2. Axial Length

    Measured using non-contact optical biometer

    Time frame: 1 year, once every 6 months (Baseline, Month 6, Month 12 Visit)

  3. Choroidal Thickness

    Measured using optical coherence tomography (OCT) scan

    Time frame: 1 year, once every 6 months (Baseline, Month 6, Month 12 Visit)

Secondary outcomes

  1. Retinal and choroidal perfusion

    Measured using optical coherence tomography angiography (OCT-A) function within OCT machine used to measure choroidal thickness.

    Time frame: 1 year, once every 6 months (Baseline, Month 6, Month 12 Visit)

  2. Corneal Curvature

    Measured using autoref/kerato/pachy/tonometer.

    Time frame: 1 year, once every 6 months (Baseline, Month 6, Month 12 Visit)

  3. Corneal Thickness

    Measured using autoref/kerato/pachy/tonometer.

    Time frame: 1 year, once every 6 months (Baseline, Month 6, Month 12 Visit)

  4. Impulse control

    Impulse control will be assessed using a validated, child-adapted task developed by collaborator Dr. Evelyn Law (NUS). The "Day and Night Cards" task or a similar task will be administered on tablets (one tablet per child). Impulse control will be quantified by the number of errors committed by the children during the task which involves shifting instructions and paradigms.

    Time frame: 1 year, once every 3 months (Baseline, Month 3, Month 6, Month 9 , Month 12 Visit)

  5. Cognitive flexibility

    Cognitive flexibility will be assessed using a validated, child-adapted task developed by collaborator Dr. Evelyn Law (NUS). The "Day and Night Cards" task or a similar task will be administered on tablets (one tablet per child). Cognitive flexibility will be quantified by the number of errors committed by the children during the task which involves shifting instructions and paradigms.

    Time frame: 1 year, once every 3 months (Baseline, Month 3, Month 6, Month 9 , Month 12 Visit)

  6. Spatial working memory

    Spatial working memory will be assessed using a validated, child-adapted task developed by collaborator Dr. Evelyn Law (NUS). The "Eight Boxes" task or a similar task will be administered on tablets (one tablet per child). Spatial working memory will be quantified by the number of errors committed by the children during the task.

    Time frame: 1 year, once every 3 months (Baseline, Month 3, Month 6, Month 9 , Month 12 Visit)

  7. Content working memory

    Content working memory will also be assessed using a validated, child-adapted task developed by collaborator Dr. Evelyn Law (NUS). The "Eight Boxes" task or a similar task will be administered on tablets (one tablet per child). Content working memory will be quantified by the number of errors committed by the children during the task when remembering the content of different items in the task (e.g., strawberry, watermelon, etc.).

    Time frame: 1 year, once every 3 months (Baseline, Month 3, Month 6, Month 9 , Month 12 Visit)

  8. Processing speed

    Processing speed will be assessed from the previous cognitive tasks (e.g., Eight Boxes and Day and Night Cards" through the investigation of reaction time (ms) in response to the content of the tasks. The tasks will be administered on tablets (one tablet per child).

    Time frame: 1 year, once every 3 months (Baseline, Month 3, Month 6, Month 9 , Month 12 Visit)

  9. Sleep quantity

    This is a secondary outcome and will depend on the days of wear of the activity and light trackers. Night time sleep quantity (minutes) will be collected through actigraphy watches given to participants.

    Time frame: 1 year or at least 1 week per month for 1 year

  10. Sleep efficiency

    This is a secondary outcome and will depend on the days of wear of the activity and light trackers. Night time sleep efficiency (%) calculated as the amount of time spent asleep (in minutes) by the total amount of time in bed (in minutes) will be measured using actigraphy watches given to participants.

    Time frame: 1 year or at least 1 week per month for 1 year

  11. Height

    Height of the participant in cm

    Time frame: 1 year, at baseline and 12 months from baseline

  12. Weight

    Weight of the participant in Kg

    Time frame: 1 year, at baseline and 12 months from baseline

  13. Visual acuity

    LogMAR visual acuity test

    Time frame: 1 year, once every 6 months (Baseline, Month 6, Month 12 Visit)

Other outcomes

  1. Daytime average light levels (lux)

    Daytime average light levels (lux) collected using wearable light sensors.

    Time frame: 1 year or at least 1 week per month for 1 year

  2. Daytime average melanopic lux

    Daytime average melanopic lux collected using wearable light sensors.

    Time frame: 1 year or at least 1 week per month for 1 year

  3. Time spent outdoors (questionnaires)

    Estimated time spent outdoors collected using questionnaires

    Time frame: 1 year or at least 1 week per month for 1 year

  4. Time spent outdoors (wearables)

    Calculated time spent outdoors collected using the wearable light sensors.

    Time frame: 1 year or at least 1 week per month for 1 year

  5. Color vision

    Color vision assessment using the Ishihara color vision test

    Time frame: Baseline

  6. Cover test (distance and near)

    Cover test to screen for strabismus

    Time frame: 1 year, repeated every 6 months

07

Study locations

5 of 5 sites recruiting
  • National University of Singapore, Yong Loo Lin School of Medicine, Department of Ophthalmology, Eye N Brain Research Lab
    Singapore, 119276, Singapore
    Recruiting
    • Najiya Sundus Kadavath Meethal, PhD · Contactlightspan@nus.edu.sg · 006591183642
    • Raymond P. Najjar, PhD · Principal investigator
  • Marymount Convent School
    Singapore, 297754, Singapore
    Recruiting
    • Najiya Sundus Kadavath Meethal, PhD · Contactlightspan@nus.edu.sg · 006591183642
    • Raymond P. Najjar, PhD · Principal investigator
  • Bedok Green Primary School
    Singapore, 469317, Singapore
    Recruiting
    • Najiya Sundus Kadavath Meethal, PhD · Contactlightspan@nus.edu.sg · 006591183642
    • Raymond P Najjar, PhD · Principal investigator
  • Westwood Primary School
    Singapore, 649188, Singapore
    Recruiting
    • Najiya Sundus Kadavath Meethal, PhD · Contactlightspan@nus.edu.sg · 006591183642
    • Raymond P Najjar, PhD · Principal investigator
  • Wellington Primary School
    Singapore, 757702, Singapore
    Recruiting
    • Najiya Sundus Kadavath Meethal, PhD · Contactlightspan@nus.edu.sg · 006591183642
    • Raymond P Najjar, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06631339
Responsible party
Raymond P. Najjar, PhD (Assistant Professor, National University of Singapore) — Principal investigator
First posted
Oct 8, 2024
Start date
Oct 21, 2024
Primary completion
Jan 26, 2027 (estimated)
Completion
Jan 26, 2027 (estimated)
Last update
Sep 23, 2025

Study contacts

Raymond P. Najjar, PhD
Contact
lightspan@nus.edu.sg
006566018519
Raymond P. Najjar, PhD
principal investigator · National University of Singapore

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion